Global Health Ltd

- As of March 2023, Medanta became a net debt-free company with a net cash surplus of INR 4,692 million. - INR 500 crore IPO proceeds were utilized largely (INR 375 crore) towards debt repayment completed in April 2023. - No explicit mention of planned new fundraising through debt or equity in the provided transcript. - The company is well capitalized to fund future expansion and growth from its robust balance sheet and strong operating cash flow. - Planned capital expenditure of around INR 1,000 crore over the next three years for capacity expansion is expected to be funded internally. - If needed, specific calls and clarifications on detailed financials can be arranged, but there is no stated intent for immediate fundraising. In summary, currently no announced or planned new fundraising through debt or equity. The company relies on a strong balance sheet and cash flow to fund expansion.

- Medanta plans to increase bed capacity from ~2,700 to ~4,000 beds over the next three years. - Total expected capex of approximately INR 1,000 crores for adding around 1,200-1,300 beds between FY24 and FY26. - INR 450 crores capex expected in the current year (FY24), including around INR 250 crores for the Noida Hospital project. - Noida facility: 550-bed hospital, expected to open in late FY25, operationalizing about 300 beds initially and scaling up as needed. - Gurgaon facility undergoing expansion with about 80 new senior doctors; adding ~30 beds in mother and child floor and ~50 beds for oncology daycare services through renovation. - Indore expansion via asset-light approach: partnering to build a 300-350 bed hospital; Medanta to equip and operate the facility. - Strong cash flows and net cash surplus of INR 4,692 million as of March 2023, well-positioned for funding future growth.

- Continued ramp-up of Patna and Lucknow facilities to full capacity, expected to drive volume and revenue growth. - Launch of new 550-bed facility in Noida and 300+ bed hospital project in Indore to expand capacity and market reach. - Addition of about 80 senior doctors and new clinical services (e.g., mother and child, lung transplant, chest surgery) at Gurgaon to boost volumes. - Focus on increasing operating efficiencies and material/employee cost optimizations to improve margins alongside revenue growth. - Tariff increases implemented in early 2023 expected to contribute positively to margins and revenue. - Strong inpatient volume growth (32% YoY) and outpatient growth (15.4% YoY) in FY23, with further growth expected as facilities mature. - Expansion into premium cancer and mother-child beds (30 and 50+ beds respectively) to drive higher value service volumes. - Stable and improving margin guidance excluding other income around 20-22%.

- Medanta projects continued deliberate and sustainable growth focusing on ramping up Patna and Lucknow facilities to full capacity. - Addition of new clinical talent, including 80 senior doctors mainly in Gurgaon, will drive volume and service expansion. - New service lines such as mother and child care, lung transplant, chest surgery, and premium cancer services are expected to boost top line. - Recently initiated tariff revisions, especially in Gurgaon, will positively impact revenue and margins going forward. - EBITDA margins improved to 24.5% in FY23; management expects margins to stabilize and potentially improve with scaling and better utilization. - New projects include a 550-bed facility in Noida and a 300+ bed hospital in Indore to further increase capacity and revenue streams. - Patna hospital, though still stabilizing, has delivered healthy margins and will contribute more profits as services like radiation oncology start.

The transcript and document do not explicitly mention any details about current or expected order book or pending orders for Medanta – Global Health Limited. The content primarily focuses on operational performance, expansion plans, patient volumes, tariff revisions, bed capacity, and financial results. There is no direct reference to order book status or pending orders. If you seek detailed information on contracts, order books, or pending orders, it may require a follow-up with the company directly or checking their official disclosures or investor presentations beyond this transcript.